A Review of Survival in Mycosis Fungoides

Abstract

Although MF is considered a cutaneous lymphoma, that is, a malignancy, it may be time to reconsider low stages of MF as precursors to malignancy analogous to the precursors to malignancies of other types or organs.

Epidemiology and prognostic factors for mycosis fungoides and Sézary syndrome in a multi‐ethnic Asian cohort: a 12‐year review

“…This possibly represents an ethnic preponderance with regard to hypopigmented MF, or perhaps simply because pigment loss is more easily appreciated in skin of colour. Neoplastic cells in hypopigmented MF were shown to be predominantly CD8 positive in previous studies . We did not determine whether this was also the case for our patients as immunohistochemistry was not routinely performed in the presence of consistent clinical and histological features.…”

“…This corroborates the positive outcome of early disease in MF in various reviews. 11,16 The overall mortality rate of 3.7% in our MF cohort is relatively low compared to other populations. In comparison, long-term studies of MF/SS have reported overall mortality of between 16.2% and 23.0% in Japan 14,17 and 26.9%-53.0% in the United States.…”

“…During the study period, there were no deaths amongst this group of patients with early‐stage disease. This corroborates the positive outcome of early disease in MF in various reviews . The overall mortality rate of 3.7% in our MF cohort is relatively low compared to other populations.…”

“…Neoplastic cells in hypopigmented MF were shown to be predominantly CD8 positive in previous studies. 16 We did not determine whether this was also the case for our patients as immunohistochemistry was not routinely performed in the presence of consistent clinical and histological features.…”

Die Diagnostik und Therapie kutaner Lymphome erfordert spezielle klinische und dermatohistologische Kenntnisse

“…Die Diagnosestellung eines kutanen Lymphoms erfordert detaillierte klinische und auch histopathologische Kenntnisse. Diese sollten im Dialog zwischen Kliniker und Dermatohistopathologen zur korrekten Diagnose führen . Die korrekte Zuordnung zu einer Hautlymphomentität ermöglicht eine fundierte Beratung des Patienten über den zu erwartenden Verlauf seiner Erkrankung und ist die Grundlage für jede therapeutische Entscheidung.…”